Comparing Olanzapine and Mirtazapine in the Improvement of Unintentional Weight Loss for Patients with Advanced Stage Cancer

Enrolling by invitation · Phase 2

Conditions studied: Anorexia Nervosa with Significantly Low Body Weight

In brief

To determine whether olanzapine or mirtazapine is more effective in preventing weight loss and appetite loss in cancer patients.

Key facts

Study ID

NCT05170919

Run by

Englewood Hospital and Medical Center

People needed

170

Starts

2022-01-20

Expected to finish

2026-12-01

Last updated by the study team

2024-09-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• • 18 years of age or older
• Able to provide informed consent
• Pathologically and/or clinically confirmed diagnosis of advanced cancer
• At any point of treatment with standard chemotherapy*
• o Scheduled to start, have discontinued or completed, or currently receiving
• Greater than or equal to 5% unintentional weight loss over the previous 3-6 months, not explained by simple starvation
• o Simple starvation is considered to be excluded when weight loss is not ameliorated by standard nutritional counseling and oral supplementation over a 2-week period).
• Life expectancy of at least 4 months
• Able to communicate well and comply with study requirements, including by phone and written logs
• Patients on Dexamethasone will be allowed

You may not qualify if…

• • Abnormal liver function defined as > twice upper limit of normal
• Elevated QTc
• o EKG performed within 1 year of enrollment will be accepted
• Total parental nutrition (TPN) or enteral feeds (PEG/PEJ) for >70% of their primary source of daily calorie intake
• Taking Marinol within 2 week of enrollment onto study

Where it is running

• Englewood Health — Englewood, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.